Aytu BioPharma, Inc. (AYTU)

Market Cap	17.25M
Revenue (ttm)	66.38M
Net Income (ttm)	-13.56M
Shares Out	9.91M
EPS (ttm)	-2.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	618,155
Open	1.850
Previous Close	1.860
Day's Range	1.700 - 1.884
52-Week Range	0.950 - 2.850
Beta	0.23
Analysts	Strong Buy
Price Target	9.17 (+427.01%)
Earnings Date	Sep 23, 2025

About AYTU

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above, and Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Kar...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Joshua Disbrow
• Employees: 102
• Stock Exchange: NASDAQ
• Ticker Symbol: AYTU
• Website: https://aytubio.com

Financial Performance

In 2025, Aytu BioPharma's revenue was $66.38 million, an increase of 1.84% compared to the previous year's $65.18 million. Losses were -$13.56 million, -14.40% less than in 2024.

Analyst Forecast

According to 3 analysts, the average rating for AYTU stock is "Strong Buy." The 12-month stock price target is $9.17, which is an increase of 427.01% from the latest price.

Price Target

$9.17

(427.01% upside)

Analyst Consensus: Strong Buy